RXDX-105 demonstrates anti-tumor efficacy in multiple preclinical cancer models driven by molecular alterations in RET or BRAF oncogenes

Molecular alterations in RET, including rearrangements and activating point mutations, have been identified as oncogenic drivers. Point mutations in RET are typically detected in multiple endocrine neoplasia (types A and B), as well as familial medullary thyroid carcinoma. RET gene rearrangements ha...

Ausführliche Beschreibung